Biogen (BIIB) Shares are Up 1.76%

Biogen (BIIB) has been under a strong bear grip, hence the stock is down -0.62% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 1.25% in the past 1 week. The stock has risen by 1.76% in the past week indicating that the buyers are active at lower levels, but the stock is down -0.75% in the past 4 weeks.

The stock has recorded a 20-day Moving Average of 0.56% and the 50-Day Moving Average is 10.38%.The 200 Day SMA reached 14.36%. Biogen Inc. is up 8.19% in the last 3-month period. Year-to-Date the stock performance stands at 2.36%.


Biogen (NASDAQ:BIIB): After opening at $311.83, the stock dipped to an intraday low of $308.66 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $318.88 and the buying power remained strong till the end. The stock closed at $313.59 for the day, a gain of 2.47% for the day session. The total traded volume was 2,233,859. The stocks close on the previous trading day was $306.03.

Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Companys marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN (rituximab), which is a monoclonal antibody for the treatment of non-Hodgkins lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.